{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:22:13Z","timestamp":1782778933695,"version":"3.54.5"},"reference-count":82,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>Coronavirus disease 2019 (COVID-19) test performance depends on predictive values in settings of increasing disease prevalence. Geospatially distributed diagnostics with minimal uncertainty facilitate efficient point-of-need strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives.\u2014<\/jats:title>\n                    <jats:p>To use original mathematics to interpret COVID-19 test metrics; assess US Food and Drug Administration Emergency Use Authorizations and Health Canada targets; compare predictive values for multiplex, antigen, polymerase chain reaction kit, point-of-care antibody, and home tests; enhance test performance; and improve decision-making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>PubMed\/newsprint-generated articles documenting prevalence. Mathematica and open access software helped perform recursive calculations, graph multivariate relationships, and visualize performance by comparing predictive value geometric mean-squared patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>Tiered sensitivity\/specificity comprised: T1, 90%, 95%; T2, 95%, 97.5%; and T3, 100%, \u226599%. Tier 1 false negatives exceeded true negatives at &amp;gt;90.5% prevalence; false positives exceeded true positives at &amp;lt;5.3% prevalence. High-sensitivity\/specificity tests reduced false negatives and false positives, yielding superior predictive values. Recursive testing improved predictive values. Visual logistics facilitated test comparisons. Antigen test quality fell off as prevalence increased. Multiplex severe acute respiratory syndrome (SARS)\u2013CoV-2)*influenza A\/B*respiratory syncytial virus testing performed reasonably well compared with tier 3. Tier 3 performance with a tier 2 confidence band lower limit will generate excellent performance and reliability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>The overriding principle is to select the best combined performance and reliability pattern for the prevalence bracket. Some public health professionals recommend repetitive testing to compensate for low sensitivity. More logically, improved COVID-19 assays with less uncertainty conserve resources. Multiplex differentiation of COVID-19 from influenza A\/B\u2013respiratory syncytial virus represents an effective strategy if seasonal flu surges next year.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2020-0716-sa","type":"journal-article","created":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T12:59:46Z","timestamp":1615208386000},"page":"797-813","source":"Crossref","is-referenced-by-count":20,"title":["The Impact of Increasing Disease Prevalence, False Omissions, and Diagnostic Uncertainty on Coronavirus Disease 2019 (COVID-19) Test Performance"],"prefix":"10.5858","volume":"145","author":[{"given":"Gerald J.","family":"Kost","sequence":"first","affiliation":[{"name":"From the Department of Pathology and Laboratory Medicine, POCT\u2022CTR, School of Medicine, University of California, Davis"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","published-online":{"date-parts":[[2021,3,8]]},"reference":[{"key":"2021062116503375300_i1543-2165-145-7-797-b01","doi-asserted-by":"crossref","unstructured":"Kost\n              GJ\n            .\n\t\t\t\t\t\n          Designing and interpreting COVID-19 diagnostics: mathematics, visual logistics, and low prevalence.\n\t\t\t\t\tArch Pathol Lab Med.\n\t\t\t\t\t2021;\n\t\t\t\t\t145(3):\n\t\t\t\t\t291\u2013\n\t\t\t\t\t307.","DOI":"10.5858\/arpa.2020-0443-SA"},{"key":"2021062116503375300_i1543-2165-145-7-797-b02","unstructured":"US Food and Drug Administration.\n          In vitro diagnostics EUAs.\n\t\t\t\t\thttps:\/\/www.fda.gov\/medical-devices\/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices\/vitro-diagnostics-euas. Accessed January 9,2021."},{"key":"2021062116503375300_i1543-2165-145-7-797-b03","unstructured":"Stenzel\n              T.\n            \n          \n          FDA virtual town hall series: immediate in effect guidance on Coronavirus (COVID-19) diagnostic tests. May 6, 2020.\n\t\t\t\t\thttps:\/\/www.fda.gov\/media\/137986\/download. Accessed January 9,2021."},{"key":"2021062116503375300_i1543-2165-145-7-797-b04","unstructured":"Health Canada.\n          COVID-19 serological testing devices: notice on sensitivity and specificity values. June 24, 2020.\n\t\t\t\t\thttps:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/covid19-industry\/medical-devices\/testing\/serological\/notice-sensitivity-specificity-values.html#toc1. Accessed January 9,2021."},{"key":"2021062116503375300_i1543-2165-145-7-797-b05","doi-asserted-by":"crossref","unstructured":"Raschke\n              RA,\n            \n            \n              Curry\n              SC,\n            \n            \n              Glenn\n              T,\n            \n            \n              Gutierrez\n              F,\n            \n            \n              Iyengar\n              S. A\n            \n          \n          Bayesian analysis of strategies to rule out COVID19 using reverse transcriptase-polymerase chain reaction (RT-PCR)\n          [published online ahead of print\n          April\n          27,\n          2020].\n\t\t\t\t\tArch Path Lab Med. doi: 10.5858\/arpa.2020-0196-LE","DOI":"10.5858\/arpa.2020-0196-LE"},{"key":"2021062116503375300_i1543-2165-145-7-797-b06","doi-asserted-by":"crossref","unstructured":"US Food and Drug Administration.\n          Template for manufacturers of molecular and antigen diagnostic COVID-19 tests for non-laboratory use: section 8, clinical evaluation, paragraphs 5 and 6, p. 16; and section 10: alternate clinical study approaches, paragraph 10 A and B,\n\t\t\t\t\tpp.16\u2013\n\t\t\t\t\t17.\n\t\t\t\t\tJuly 29, 2020.https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-posts-new-template-home-and-over-counter-diagnostic-tests-use-non. Accessed January 9,2021.","DOI":"10.1089\/clinomi.08.02.12"},{"key":"2021062116503375300_i1543-2165-145-7-797-b07","doi-asserted-by":"crossref","unstructured":"Kennedy-Shaffer\n              L,\n            \n            \n              Baym\n              M,\n            \n            \n              Hanage\n              WP\n            .\n\t\t\t\t\t\n          Perfect as the enemy of the good: using low-sensitivity tests to mitigate +SARS-CoV-2 outbreaks.\n\t\t\t\t\t2020.\n\t\t\t\t\tDigital Access to Scholarship at Harvard Web site.https:\/\/dash.harvard.edu\/handle\/1\/37363184. Accessed January 9,2021.","DOI":"10.1016\/S2666-5247(21)00004-5"},{"key":"2021062116503375300_i1543-2165-145-7-797-b08","unstructured":"US Food and Drug Administration.\n          Emergency Use Authorization: cobas SARS-CoV-2 & Influenza A\/B, instructions for users,\n\t\t\t\t\tTable 22, p. 38 of 44. September 3, 2020.https:\/\/www.fda.gov\/media\/141887\/download. Accessed January 9,2021."},{"key":"2021062116503375300_i1543-2165-145-7-797-b09","doi-asserted-by":"crossref","unstructured":"Hansen\n              G,\n            \n            \n              Marino\n              J,\n            \n            \n              Wang\n              ZX,\n            \n            et al.\n          \n          Clinical performance of the point-of-care cobas Liat for detection of SARS-CoV-2 in 20 minutes: a multicenter study.\n\t\t\t\t\tJ Clin Microbiol.\n\t\t\t\t\t2021;\n\t\t\t\t\t59(2):\n\t\t\t\t\te02811\u2013\n\t\t\t\t\te02820.","DOI":"10.1128\/JCM.02811-20"},{"key":"2021062116503375300_i1543-2165-145-7-797-b10","unstructured":"Cepheid Xpert Xpress SARS-CoV-2\/Flu\/RSV.\n          US Food and Drug Administration Web site.\n\t\t\t\t\thttps:\/\/www.fda.gov\/media\/142438\/download. AccessedJanuary9,2021."},{"key":"2021062116503375300_i1543-2165-145-7-797-b11","unstructured":"Seegene Inc.\n          Seegene introduces a high throughput 8-plex Test for Flu A, Flu B, RSV and COVID-19 with dual internal controls\n          [press release].\n          Cision PR Newswire.\n\t\t\t\t\tSeptember 8, 2020.https:\/\/www.prnewswire.com\/news-releases\/seegene-introduces-a-high-throughput-8-plex-test-for-flu-a-flu-b-rsv-and-covid-19-with-dual-internal-controls-301125437.html. Accessed January 9,2021."},{"key":"2021062116503375300_i1543-2165-145-7-797-b12","unstructured":"US Food and Drug Administration.\n          In vitro diagnostic EUAs: individual EUAs for antigen diagnostic tests for SARS-CoV-2.\n\t\t\t\t\thttps:\/\/www.fda.gov\/medical-devices\/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices\/vitro-diagnostics-euas#individual-antigen. Accessed January 9,2021."},{"key":"2021062116503375300_i1543-2165-145-7-797-b13","unstructured":"US Food and Drug Administration.\n          Visby medical package insert: COVID-19. September 16, 2020.\n\t\t\t\t\thttps:\/\/www.fda.gov\/media\/142228\/download. Accessed January 9,2021."},{"key":"2021062116503375300_i1543-2165-145-7-797-b14","unstructured":"US Food and Drug Administration.\n          Visby medical package insert: COVID-19 point of care. February 8, 2021.\n\t\t\t\t\thttps:\/\/www.fda.gov\/media\/145917\/download. Accessed February 25,2021."},{"key":"2021062116503375300_i1543-2165-145-7-797-b15","unstructured":"US Food and Drug Administration.\n          Coronavirus (COVID-19) update: FDA authorizes first point-of-care antibody test for COVID-19.\n\t\t\t\t\thttps:\/\/www.fda.gov\/media\/139789\/download. Accessed January 9,2021."},{"key":"2021062116503375300_i1543-2165-145-7-797-b16","unstructured":"US Food and Drug Administration.\n          EUA authorized serology test performance: Assure COVID-19 IgG\/IgM rapid test device. October 9, 2020.\n\t\t\t\t\thttps:\/\/www.fda.gov\/medical-devices\/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices\/eua-authorized-serology-test-performance. Accessed January 9,2021."},{"key":"2021062116503375300_i1543-2165-145-7-797-b17","doi-asserted-by":"crossref","unstructured":"Mathur\n              G,\n            \n            \n              Mathur\n              S.\n            \n          \n          Antibody testing for COVID-19: can it be used as a screening tool in areas with low prevalence?\n          \n            Am J Clin Pathol\n          .\n\t\t\t\t\t2020;\n\t\t\t\t\t154:\n\t\t\t\t\t1\u2013\n\t\t\t\t\t3.","DOI":"10.1093\/ajcp\/aqaa082"},{"key":"2021062116503375300_i1543-2165-145-7-797-b18","unstructured":"US Food and Drug Administration.\n          Coronavirus (COVID-19) update: FDA authorizes antigen test as first over-the-counter fully at-home diagnostic test for COVID-19. December 15, 2020.\n\t\t\t\t\thttps:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-antigen-test-first-over-counter-fully-home-diagnostic. Accessed January 9,2021."},{"key":"2021062116503375300_i1543-2165-145-7-797-b19","unstructured":"US Food and Drug Administration.\n          Individual EUAs for antigen diagnostic tests for SARS-CoV-2: ellume Information for Users.\n\t\t\t\t\thttps:\/\/www.fda.gov\/media\/144592\/download. Accessed January 9,2021."},{"key":"2021062116503375300_i1543-2165-145-7-797-b20","unstructured":"World Health Organization.\n          \n            Target Product Profiles for Priority Diagnostics to Support Response to the COVID-19 Pandemic v.1.0\n          .\n\t\t\t\t\tGeneva, Switzerland:\n\t\t\t\t\tWHO;2020."},{"key":"2021062116503375300_i1543-2165-145-7-797-b21","doi-asserted-by":"crossref","unstructured":"Ghaffari\n              A,\n            \n            \n              Meurant\n              R,\n            \n            \n              Ardakani\n              A.\n            \n          \n          COVID-19 point-of-care diagnostics that satisfy global target product profiles.\n\t\t\t\t\tDiagnostics.\n\t\t\t\t\t2021;\n\t\t\t\t\t11(115):\n\t\t\t\t\t1\u2013\n\t\t\t\t\t12.","DOI":"10.3390\/diagnostics11010115"},{"key":"2021062116503375300_i1543-2165-145-7-797-b22","doi-asserted-by":"crossref","unstructured":"Dugdale\n              CM,\n            \n            \n              Anahtar\n              MN,\n            \n            \n              Chiosi\n              JJ,\n            \n            et al.\n          \n          Clinical, laboratory, and radiological characteristics of patients with initial false negative SARS-CoV-2 nucleic acid amplification test results.\n\t\t\t\t\tOxford University Open Forum Infectious Diseases.\n\t\t\t\t\tNovember24,2020.\n\t\t\t\t\tdoi: 10.1093\/ofid\/ofaa559","DOI":"10.1093\/ofid\/ofaa559"},{"key":"2021062116503375300_i1543-2165-145-7-797-b23","doi-asserted-by":"crossref","unstructured":"Volz\n              E,\n            \n            \n              Mishra\n              S,\n            \n            \n              Chand\n              M,\n            \n            et al.\n          \n          Transmission of SARS-CoV-2 lineage B.1.1.7 in England: insights from linking epidemiological and genetic data\n          [posted online\n          January\n          4,\n          2021].\n\t\t\t\t\tmedRxiv.\n\t\t\t\t\tdoi: 10.1101\/2020.12.30.20249034","DOI":"10.1101\/2020.12.30.20249034"},{"key":"2021062116503375300_i1543-2165-145-7-797-b24","unstructured":"US Food and Drug Administration.\n          FDA Virtual Townhall Series.\n\t\t\t\t\tDecember 16, 2020.https:\/\/www.fda.gov\/media\/144735\/download AccessedJanuary9,2021."},{"key":"2021062116503375300_i1543-2165-145-7-797-b25","doi-asserted-by":"crossref","unstructured":"Prince-Guerra\n              JL,\n            \n            \n              Almandares\n              O,\n            \n            \n              Nolen\n              LD,\n            \n            et al.\n          \n          Evaluation of Abbott BinaxNOW rapid antigen test for SARS-CoV-2 infection at two community-based testing sites\u2014Pima County, Arizona, November 3-17, 2020.\n\t\t\t\t\tMMWR Morb Mortal Wkly Rep.\n\t\t\t\t\t2021;\n\t\t\t\t\t70:\n\t\t\t\t\t100\u2013\n\t\t\t\t\t105.","DOI":"10.15585\/mmwr.mm7003e3"},{"key":"2021062116503375300_i1543-2165-145-7-797-b26","unstructured":"Mathews\n              AW\n            .\n\t\t\t\t\t\n          Testing maker probes false-positive results.\n\t\t\t\t\tWall Street Journal.\n\t\t\t\t\t2020;\n\t\t\t\t\t276(64):\n\t\t\t\t\tA6."},{"key":"2021062116503375300_i1543-2165-145-7-797-b27","unstructured":"Mathews\n              AW,\n            \n            \n              Abbott\n              B.\n            \n          \n          U.S. orders Nevada to allow rapid tests in nursing homes.\n\t\t\t\t\tWall Street Journal.\n\t\t\t\t\t2020;\n\t\t\t\t\t276(86):\n\t\t\t\t\tA8."},{"key":"2021062116503375300_i1543-2165-145-7-797-b28","unstructured":"Abbott\n              B,\n            \n            \n              Mathews\n              AW\n            .\n\t\t\t\t\t\n          Nevada lifts block on some rapid tests.\n\t\t\t\t\tWall Street Journal.\n\t\t\t\t\t2020;\n\t\t\t\t\t276(87):\n\t\t\t\t\tA6."},{"key":"2021062116503375300_i1543-2165-145-7-797-b29","unstructured":"The COVID Tracking Project.\n          The long-term care COVID tracker.\n\t\t\t\t\thttps:\/\/covidtracking.com\/data\/long-term-care. Accessed February 20,2021."},{"key":"2021062116503375300_i1543-2165-145-7-797-b30","unstructured":"Douglas\n              J,\n            \n            \n              Meichtry\n              S,\n            \n            \n              Barnett\n              A.\n            \n          \n          Europe outpaces U.S. in key case gauge: France declares state of emergency, imposes curfew on Paris as virus flares up on continent.\n\t\t\t\t\tWall Street Journal.\n\t\t\t\t\t2020;\n\t\t\t\t\t276(90):\n\t\t\t\t\tA9."},{"key":"2021062116503375300_i1543-2165-145-7-797-b31","unstructured":"Korn\n              M.\n            \n          \n          A testing lab helps keep northeast colleges open.\n\t\t\t\t\tWall Street Journal.\n\t\t\t\t\t2020;\n\t\t\t\t\t276(92):\n\t\t\t\t\tA3."},{"key":"2021062116503375300_i1543-2165-145-7-797-b32","unstructured":"Mathews\n              A.\n            \n          \n          Reinfection case indicates recovered patients are at risk.\n\t\t\t\t\tWall Street Journal.\n\t\t\t\t\t2020;\n\t\t\t\t\t276(88):\n\t\t\t\t\tA7."},{"key":"2021062116503375300_i1543-2165-145-7-797-b33","doi-asserted-by":"crossref","unstructured":"Tillett\n              RL,\n            \n            \n              Sevinsky\n              JR,\n            \n            \n              Hartley\n              PD,\n            \n            et al.\n          \n          Genomic evidence for reinfection with SARS-CoV-2: a case study.\n\t\t\t\t\tLancet Infect Dis.\n\t\t\t\t\t2021;\n\t\t\t\t\t21(1):\n\t\t\t\t\t52\u2013\n\t\t\t\t\t58.","DOI":"10.1016\/S1473-3099(20)30764-7"},{"key":"2021062116503375300_i1543-2165-145-7-797-b34","doi-asserted-by":"crossref","unstructured":"Iwasaki\n              A.\n            \n          \n          What reinfections mean for COVID-19.\n\t\t\t\t\tLancet Infect Dis.\n\t\t\t\t\t2021;\n\t\t\t\t\t21(1):\n\t\t\t\t\t3\u2013\n\t\t\t\t\t5.","DOI":"10.1016\/S1473-3099(20)30783-0"},{"key":"2021062116503375300_i1543-2165-145-7-797-b35","unstructured":"Pancevski\n              B.\n            \n          \n          European alarm grows over surge\u2013rise in COVID-19 cases coincides with peak tourist season, worries about complacency.\n\t\t\t\t\tWall Street Journal.\n\t\t\t\t\t2020;\n\t\t\t\t\t276(24):\n\t\t\t\t\tA7."},{"key":"2021062116503375300_i1543-2165-145-7-797-b36","unstructured":"Sider\n              A.\n            \n          \n          United Airlines to offer Covid tests to some travelers.\n\t\t\t\t\tWall Street Journal.\n\t\t\t\t\t2020;\n\t\t\t\t\t276(73):\n\t\t\t\t\tB3."},{"key":"2021062116503375300_i1543-2165-145-7-797-b37","unstructured":"McCartney\n              S.\n            \n          \n          Can airport Covid testing get people flying again?\n          \n            Wall Street Journal\n          .\n\t\t\t\t\t2020;\n\t\t\t\t\t276(84):\n\t\t\t\t\tA11."},{"key":"2021062116503375300_i1543-2165-145-7-797-b38","unstructured":"US Food and Drug Administration.\n          Coronavirus (COVID-19) update: FDA authorizes first standalone at-home sample collection kit that can be used with certain authorized tests. May 16, 2020.\n\t\t\t\t\thttps:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-first-standalone-home-sample-collection-kit-can-be-used. Accessed January 9,2021."},{"key":"2021062116503375300_i1543-2165-145-7-797-b39","unstructured":"US Food and Drug Administration.\n          Coronavirus (COVID-19) update: FDA authorizes first diagnostic test using at-home collection of saliva specimens. May 8, 2020.\n\t\t\t\t\thttps:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-first-diagnostic-test-using-home-collection-saliva. Accessed January 9,2021."},{"key":"2021062116503375300_i1543-2165-145-7-797-b40","unstructured":"Herrera\n              S.\n            \n          \n          Amazon reveals Covid cases in workforce.\n\t\t\t\t\tWall Street Journal.\n\t\t\t\t\t2020;\n\t\t\t\t\t276(79):\n\t\t\t\t\tB4."},{"key":"2021062116503375300_i1543-2165-145-7-797-b41","doi-asserted-by":"crossref","unstructured":"Kwok\n              KO,\n            \n            \n              Lai\n              F,\n            \n            \n              Wei\n              WI,\n            \n            \n              Wong\n              SYS,\n            \n            \n              Tang\n              JWT\n            .\n\t\t\t\t\t\n          Herd immunity\u2013estimating the level required to halt the COVID-19 epidemics in affected countries.\n\t\t\t\t\tJ Infect.\n\t\t\t\t\t2020;\n\t\t\t\t\t80:\n\t\t\t\t\te32\u2013\n\t\t\t\t\te33.","DOI":"10.1016\/j.jinf.2020.03.027"},{"key":"2021062116503375300_i1543-2165-145-7-797-b42","unstructured":"Kost\n              GJ\n            .\n\t\t\t\t\t\n          \n            Protecting Americans from Highly Infectious Diseases Through the Creation, Dissemination, and Promotion of National Point-of-care Testing Policy and Guidelines\n          .\n\t\t\t\t\tDavis, CA:\n\t\t\t\t\tKnowledge Optimization;2017."},{"key":"2021062116503375300_i1543-2165-145-7-797-b43","doi-asserted-by":"crossref","unstructured":"Gomez-Ochoa\n              SA,\n            \n            \n              Franco\n              OH,\n            \n            \n              Rojas\n              LZ,\n            \n            et al.\n          \n          COVID-19 in healthcare workers: a living systematic review and meta-analysis of prevalence, risk factors, clinical characteristics, and outcomes.\n\t\t\t\t\tAm J Epidemiol.\n\t\t\t\t\t2021;\n\t\t\t\t\t190(1):\n\t\t\t\t\t161\u2013\n\t\t\t\t\t175.","DOI":"10.1093\/aje\/kwaa191"},{"key":"2021062116503375300_i1543-2165-145-7-797-b44","doi-asserted-by":"crossref","unstructured":"Kost\n              GJ\n            .\n\t\t\t\t\t\n          Geospatial hotspots need point-of-care strategies to stop highly infectious outbreaks: ebola and coronavirus.\n\t\t\t\t\tArch Pathol Lab Med.\n\t\t\t\t\t2020;\n\t\t\t\t\t144(10):\n\t\t\t\t\t1166\u2013\n\t\t\t\t\t1190.","DOI":"10.5858\/arpa.2020-0172-RA"},{"key":"2021062116503375300_i1543-2165-145-7-797-b45","doi-asserted-by":"crossref","unstructured":"Neilan\n              AM,\n            \n            \n              Losina\n              E,\n            \n            \n              Bangs\n              AC,\n            \n            et al.\n          \n          Clinical impact, costs, and cost-effectiveness of expanded SARS-CoV-2 testing in Massachusetts\n          [published online ahead of print\n          September\n          18,\n          2020].\n\t\t\t\t\tClin Infect Dis. doi: 10.1093\/cid\/ciaa1418","DOI":"10.1093\/cid\/ciaa1418"},{"key":"2021062116503375300_i1543-2165-145-7-797-b46","unstructured":"Abbott\n              B,\n            \n            \n              Krouse\n              S.\n            \n          \n          Rapid Covid-19 tests go unused.\n\t\t\t\t\tWall Street Journal.\n\t\t\t\t\t2021;\n\t\t\t\t\t277:\n\t\t\t\t\tA1,A6."},{"key":"2021062116503375300_i1543-2165-145-7-797-b47","doi-asserted-by":"crossref","unstructured":"Wu\n              SL,\n            \n            \n              Mertens\n              AN,\n            \n            \n              Crider\n              YS,\n            \n            et al.\n          \n          Substantial underestimation of SARS-CoV-2 infection in the United States.\n\t\t\t\t\tNat Commun.\n\t\t\t\t\t2020;\n\t\t\t\t\t11(4507):\n\t\t\t\t\t1\u2013\n\t\t\t\t\t11.","DOI":"10.1038\/s41467-020-18272-4"},{"key":"2021062116503375300_i1543-2165-145-7-797-b48","doi-asserted-by":"crossref","unstructured":"Buchan\n              BW,\n            \n            \n              Hoff\n              JS,\n            \n            \n              Cmehlin\n              CG,\n            \n            et al.\n          \n          Distribution of SARS-CoV-2 PCR cycle threshold values provide practical insight into overall and target-specific sensitivity among symptomatic patients.\n\t\t\t\t\tAm J Clin Pathol.\n\t\t\t\t\t2020;\n\t\t\t\t\t154(4):\n\t\t\t\t\t479\u2013\n\t\t\t\t\t485.","DOI":"10.1093\/ajcp\/aqaa133"},{"key":"2021062116503375300_i1543-2165-145-7-797-b49","doi-asserted-by":"crossref","unstructured":"La Scolla\n              B,\n            \n            \n              Le Bideau\n              M,\n            \n            \n              Andreani\n              J,\n            \n            et al.\n          \n          Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards.\n\t\t\t\t\tEur J Clin Microbiol Infect Dis.\n\t\t\t\t\t2020;\n\t\t\t\t\t39(6):\n\t\t\t\t\t1059\u2013\n\t\t\t\t\t1061.","DOI":"10.1007\/s10096-020-03913-9"},{"key":"2021062116503375300_i1543-2165-145-7-797-b50","unstructured":"US Food and Drug Administration.\n          Risk of false results with the Curative SARS-CoV-2 test for COVOD-19: FDA safety recommendation. January 4, 2021.\n\t\t\t\t\thttps:\/\/www.fda.gov\/medical-devices\/safety-communications\/risk-false-results-curative-sars-cov-2-test-covid-19-fda-safety-communication. Accessed January 4,2021."},{"key":"2021062116503375300_i1543-2165-145-7-797-b51","unstructured":"National Academies of Sciences, Engineering, and Medicine.\n          \n            COVID-19 Testing Strategies for Colleges and Universities\n          .\n\t\t\t\t\tWashington, DC:\n\t\t\t\t\tThe National Academies Press;\n\t\t\t\t\t2020."},{"key":"2021062116503375300_i1543-2165-145-7-797-b52","doi-asserted-by":"crossref","unstructured":"Winnett\n              A,\n            \n            \n              Cooper\n              MM,\n            \n            \n              Shelby\n              N,\n            \n            et al.\n          \n          SARS-CoV-2 viral load in saliva rises gradually and to moderate levels in some humans\n          [posted online\n          December\n          11,\n          2020].\n\t\t\t\t\tmedRxiv.\n\t\t\t\t\tdoi: 10.1101\/2020.12.09.20239467","DOI":"10.1101\/2020.12.09.20239467"},{"key":"2021062116503375300_i1543-2165-145-7-797-b53","doi-asserted-by":"crossref","unstructured":"Senok\n              A,\n            \n            \n              Alsuwaidi\n              H,\n            \n            \n              Atrah\n              Y,\n            \n            et al.\n          \n          Saliva as an alternative specimen for molecular COVOD-19 testing in community settings and population-based screening.\n\t\t\t\t\tInfect Drug Resist.\n\t\t\t\t\t2020;\n\t\t\t\t\t13:\n\t\t\t\t\t3393\u2013\n\t\t\t\t\t3399.","DOI":"10.2147\/IDR.S275152"},{"key":"2021062116503375300_i1543-2165-145-7-797-b54","doi-asserted-by":"crossref","unstructured":"Czumbel\n              LM,\n            \n            \n              Kiss\n              S,\n            \n            \n              Farkas\n              N,\n            \n            et al.\n          \n          Saliva as a candidate for COVID-198 diagnostic testing: a meta-analysis.\n\t\t\t\t\tFront Med.\n\t\t\t\t\t2020;\n\t\t\t\t\t7(465):\n\t\t\t\t\t1\u2013\n\t\t\t\t\t10.","DOI":"10.3389\/fmed.2020.00465"},{"key":"2021062116503375300_i1543-2165-145-7-797-b55","unstructured":"Michelmore\n              RW\n            .\n\t\t\t\t\t\n          Campus ready COVID-19 testing, University of California, Davis. Technical FAQ: how accurate is it?\n          UC Davis Web site.\n          \n            https:\/\/campusready.ucdavis.edu\/testing-response\/covid19-screening#faq. Accessed January 13,\n          2020."},{"key":"2021062116503375300_i1543-2165-145-7-797-b56","doi-asserted-by":"crossref","unstructured":"Deckert\n              A,\n            \n            \n              Anders\n              S,\n            \n            \n              de Allegri\n              M,\n            \n            et al.\n          \n          Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomized, two-factorial controlled study.\n\t\t\t\t\tTrials.\n\t\t\t\t\t2021:\n\t\t\t\t\t22(39):\n\t\t\t\t\t1\u2013\n\t\t\t\t\t4.","DOI":"10.1186\/s13063-020-04982-z"},{"key":"2021062116503375300_i1543-2165-145-7-797-b57","doi-asserted-by":"crossref","unstructured":"Fernandez-Gonzalez\n              M,\n            \n            \n              Agullo\n              V,\n            \n            \n              de la Rica\n              V,\n            \n            et al.\n          \n          Performance of saliva specimens for the molecular detection of SARS-CoV-2 in the community setting: does sample collection method mater?\n          [published online ahead of print\n          January\n          8,\n          2021].\n\t\t\t\t\tJ Clin Microbiol.doi: 10.1128\/JCM.03033-20","DOI":"10.1128\/JCM.03033-20"},{"key":"2021062116503375300_i1543-2165-145-7-797-b58","doi-asserted-by":"crossref","unstructured":"Zhang\n              K,\n            \n            \n              Shoukat\n              A,\n            \n            \n              Crystal\n              W,\n            \n            et al.\n          \n          Routine saliva testing for the identification of silent COVID-10 infections in healthcare workers\n          [published online ahead of print\n          January\n          11,\n          2021].\n\t\t\t\t\tInfect Control Hosp Epidemiol.2021.doi: 10.1017\/ice.2020.1413","DOI":"10.1017\/ice.2020.1413"},{"key":"2021062116503375300_i1543-2165-145-7-797-b59","doi-asserted-by":"crossref","unstructured":"Bastos\n              ML,\n            \n            \n              Perlman-Arrow\n              S,\n            \n            \n              Menzies\n              D,\n            \n            \n              Campbell\n              JR\n            .\n\t\t\t\t\t\n          The sensitivity and costs of testing for SARS-CoV-2 infection with saliva versus nasopharyngeal swabs\n          [published online ahead of print\n          January\n          12,\n          2021].\n\t\t\t\t\tAnn Intern Med.2021.doi: 10.7326\/M20-6569","DOI":"10.7326\/M20-6569"},{"key":"2021062116503375300_i1543-2165-145-7-797-b60","unstructured":"National Academies of Sciences, Engineering, and Medicine.\n          \n            Rapid Expert Consultation on Critical Issues in Diagnostic Testing for the COVID-19 Pandemic (November 9, 2020)\n          .\n\t\t\t\t\tWashington, DC:\n\t\t\t\t\tThe National Academies Press;\n\t\t\t\t\t2020."},{"key":"2021062116503375300_i1543-2165-145-7-797-b61","unstructured":"Kost\n              GJ,\n            \n            \n              Curtis\n              CM,\n            \n          \n          eds.\n          \n            Global Point of Care: Strategies for Disasters, Emergencies, and Public Health Preparedness\n          .\n\t\t\t\t\tWashington, DC:\n\t\t\t\t\tAACC Press-Elsevier;2015."},{"key":"2021062116503375300_i1543-2165-145-7-797-b62","doi-asserted-by":"crossref","unstructured":"Johansson\n              MA,\n            \n            \n              Quandelacy\n              TM,\n            \n            \n              Kada\n              S,\n            \n            et al.\n          \n          SARS-CoV-2 transmission from people without COVID-19 symptoms.\n\t\t\t\t\tJAMA Netw Open.\n\t\t\t\t\t2021;\n\t\t\t\t\t4(1):\n\t\t\t\t\te2035057.\n\t\t\t\t\tdoi: 10.1001\/jamanetworkopen.2020.35057","DOI":"10.1001\/jamanetworkopen.2020.35057"},{"key":"2021062116503375300_i1543-2165-145-7-797-b63","unstructured":"Pancevski\n              B.\n            \n          \n          Rapid tests blossom amid rise in cases.\n\t\t\t\t\tWall Street Journal.\n\t\t\t\t\t2020;\n\t\t\t\t\t276(87):\n\t\t\t\t\tA7."},{"key":"2021062116503375300_i1543-2165-145-7-797-b64","unstructured":"Colchester\n              M.\n            \n          \n          Europe's climbing load strains testing programs.\n\t\t\t\t\tWall Street Journal.\n\t\t\t\t\t2020;\n\t\t\t\t\t276(84):\n\t\t\t\t\tA8."},{"key":"2021062116503375300_i1543-2165-145-7-797-b65","unstructured":"Vinluan\n              F.\n            \n          \n          COVID-19 drives new push for CRISPR-based home diagnostics (with commentary by Dr. Kost).\n\t\t\t\t\tTimmerman Report.\n\t\t\t\t\tDecember 1, 2020. https:\/\/timmermanreport.com\/2020\/12\/covid-19-drives-new-push-for-crispr-based-home-diagnostics\/ AccessedJanuary9,2021."},{"key":"2021062116503375300_i1543-2165-145-7-797-b66","doi-asserted-by":"crossref","unstructured":"Kost\n              GJ,\n            \n            \n              Zadran\n              A,\n            \n            \n              Zadran\n              L,\n            \n            \n              Ventura\n              I.\n            \n          \n          Point-of-care testing curriculum and accreditation for public health\u2013enabling preparedness, response, and higher standards of care at points of need.\n\t\t\t\t\tFront Public Health.\n\t\t\t\t\t2019;\n\t\t\t\t\t8(385):\n\t\t\t\t\t1\u2013\n\t\t\t\t\t15.","DOI":"10.3389\/fpubh.2018.00385"},{"key":"2021062116503375300_i1543-2165-145-7-797-b67","doi-asserted-by":"crossref","unstructured":"Kost\n              GJ,\n            \n            \n              Zadran\n              A.\n            \n          \n          Schools of public health should be accredited for, and teach the principles and practice of point-of-care testing.\n\t\t\t\t\tJ Appl Lab Med.\n\t\t\t\t\t2019;\n\t\t\t\t\t4:\n\t\t\t\t\t278\u2013\n\t\t\t\t\t283.","DOI":"10.1373\/jalm.2019.029249"},{"key":"2021062116503375300_i1543-2165-145-7-797-b68","unstructured":"Kost\n              GJ\n            .\n\t\t\t\t\t\n          Public health education should include point-of-care testing\u2013lessons learned from the COVID-19 pandemic.\n          \n            EJIFCC\n          .\n\t\t\t\t\t2021;\n\t\t\t\t\tin press."},{"key":"2021062116503375300_i1543-2165-145-7-797-b69","doi-asserted-by":"crossref","unstructured":"Kost\n              GJ\n            .\n\t\t\t\t\t\n          Geospatial science and point-of-care testing: creating solutions for population access, emergencies, outbreaks, and disasters.\n\t\t\t\t\tFront Public Health.\n\t\t\t\t\t2019;\n\t\t\t\t\t7(329):\n\t\t\t\t\t1\u2013\n\t\t\t\t\t31.","DOI":"10.3389\/fpubh.2019.00329"},{"key":"2021062116503375300_i1543-2165-145-7-797-b70","doi-asserted-by":"crossref","unstructured":"Curtis\n              A,\n            \n            \n              Ajayakumar\n              J,\n            \n            \n              Curtis\n              J,\n            \n            et al.\n          \n          Geographic monitoring for early disease detection (GeoMMED).\n\t\t\t\t\tNat Res Sci Rep.\n\t\t\t\t\t2020;\n\t\t\t\t\t10:\n\t\t\t\t\t21753.\n\t\t\t\t\tdoi: 10.1038\/s41598-020-78704-5","DOI":"10.1038\/s41598-020-78704-5"},{"key":"2021062116503375300_i1543-2165-145-7-797-b71","doi-asserted-by":"crossref","unstructured":"Kalyatanda\n              GS,\n            \n            \n              Archibald\n              LK,\n            \n            \n              Patnala\n              S,\n            \n            et al.\n          \n          No human exists in isolation or as an island: The outcomes of a multidisciplinary, global, and context-specific COVID-19 consortium.\n\t\t\t\t\tAm J Dis Med.\n\t\t\t\t\t2020;\n\t\t\t\t\t15:\n\t\t\t\t\t219\u2013\n\t\t\t\t\t222.","DOI":"10.5055\/ajdm.2020.0350"},{"key":"2021062116503375300_i1543-2165-145-7-797-b72","doi-asserted-by":"crossref","unstructured":"Kost\n              GJ,\n            \n            \n              Katip\n              P,\n            \n            \n              Vansith\n              K,\n            \n            \n              Negash\n              H.\n            \n          \n          The final frontier for point of care: performance, resilience, and culture.\n\t\t\t\t\tPoint of Care.\n\t\t\t\t\t2013;\n\t\t\t\t\t12(1):\n\t\t\t\t\t1\u2013\n\t\t\t\t\t8.","DOI":"10.1097\/POC.0b013e318266b7fe"},{"key":"2021062116503375300_i1543-2165-145-7-797-b73","unstructured":"Kost\n              GJ,\n            \n            \n              Ferguson\n              WJ,\n            \n            \n              Kost\n              LE\n            .\n\t\t\t\t\t\n          Principles of point of care culture, the spatial care pathTM, and enabling community and global resilience.\n\t\t\t\t\te-Journal IFCC.\n\t\t\t\t\t2014;\n\t\t\t\t\t25(2):\n\t\t\t\t\t134\u2013\n\t\t\t\t\t153."},{"key":"2021062116503375300_i1543-2165-145-7-797-b74","unstructured":"Kost\n              GJ,\n            \n            \n              Zhou\n              Y,\n            \n            \n              Katip\n              P.\n            \n          \n          Understanding point of care culture improves resilience and standards of care in limited-resource countries.\n\t\t\t\t\tIn:KostGJ,CurtisCM,eds.Global Point of Care: Strategies for Disasters, Emergencies, and Public Health Preparedness.\n\t\t\t\t\tWashington, DC:\n\t\t\t\t\tAACC Press-Elsevier;2015:\n\t\t\t\t\t471\u2013\n\t\t\t\t\t490."},{"key":"2021062116503375300_i1543-2165-145-7-797-b75","doi-asserted-by":"crossref","unstructured":"Liu\n              X,\n            \n            \n              Zhu\n              X,\n            \n            \n              Kost\n              GJ,\n            \n            et al.\n          \n          The creation of point-of-careology.\n\t\t\t\t\tPoint of Care.\n\t\t\t\t\t2019;\n\t\t\t\t\t18:\n\t\t\t\t\t77\u2013\n\t\t\t\t\t84.","DOI":"10.1097\/POC.0000000000000191"},{"key":"2021062116503375300_i1543-2165-145-7-797-b76","doi-asserted-by":"crossref","unstructured":"Carter\n              JG,\n            \n            \n              Iturbe\n              LO,\n            \n            \n              Duprey\n              J-LHA,\n            \n            et al.\n          \n          Sub-5-minute detection of SARS-CoV-2 RNA using a reverse transcriptase-free exponential amplification reaction, RTF-EXPAR\n          [posted online\n          January\n          4,\n          2021].\n\t\t\t\t\tmedRxiv.\n\t\t\t\t\tdoi: https:\/\/doi.org\/10.1101\/2020.12.31.20248236","DOI":"10.1101\/2020.12.31.20248236"},{"key":"2021062116503375300_i1543-2165-145-7-797-b77","doi-asserted-by":"crossref","unstructured":"Dinnes\n              J,\n            \n            \n              Deeks\n              JJ,\n            \n            \n              Adriano\n              A,\n            \n            et al.\n          \n          Rapid, point-of-care antigen tests and molecular-based tests for diagnosis of SARS-CoV-2 infection\n          [review].\n          August 26, 2020.\n          \n            Cochrane Database Syst Rev.\n          \n          2020;\n\t\t\t\t\t8:\n\t\t\t\t\tCD013705.","DOI":"10.1002\/14651858.CD013705"},{"key":"2021062116503375300_i1543-2165-145-7-797-b78","unstructured":"International Federation of Clinical Chemistry and Laboratory Medicine.\n          Information guide on COVID-19. Updated December 2020.\n\t\t\t\t\thttps:\/\/www.ifcc.org\/resources-downloads\/ifcc-information-guide-on-covid-19-introduction\/. Accessed January 9,2021."},{"key":"2021062116503375300_i1543-2165-145-7-797-b79","unstructured":"Kamps\n              BS,\n            \n            \n              Hoffmann\n              C.\n            \n          \n          \n            COVID Reference\u2013The COVID Textbook. 6th ed.\n          Hamburg:\n\t\t\t\t\tSteinhauser Verlag;\n\t\t\t\t\t2021.\n\t\t\t\t\thttps:\/\/covidreference.com. Accessed February 25, 2021."},{"key":"2021062116503375300_i1543-2165-145-7-797-b80","doi-asserted-by":"crossref","unstructured":"Kost\n              GJ\n            .\n\t\t\t\t\t\n          Newdemics, public health, small-world networks, and point-of-care testing.\n\t\t\t\t\tPoint of Care.\n\t\t\t\t\t2006;\n\t\t\t\t\t5(4):\n\t\t\t\t\t138\u2013\n\t\t\t\t\t144.","DOI":"10.1097\/01.poc.0000243982.38385.d2"},{"key":"2021062116503375300_i1543-2165-145-7-797-b81","unstructured":"Kost\n              GJ\n            .\n\t\t\t\t\t\n          Point-of-care testing for pandemic management.\n\t\t\t\t\tLab Insights.\n\t\t\t\t\tAugust 25, 2020.https:\/\/www.labinsights.com\/get-inspired\/content\/point-care-testing-pandemic-management-interview-dr-gerald-kost%3FcLangCode%3Denglish. Accessed January 9,2021."},{"key":"2021062116503375300_i1543-2165-145-7-797-b82","doi-asserted-by":"crossref","unstructured":"Kost\n              GJ\n            .\n\t\t\t\t\t\n          \n            The Impact of Increasing Prevalence, False Omissions, and Diagnostic Uncertainty on COVID-19 Tests and the Future of Point-of-Care Testing\n          .\n\t\t\t\t\tBoston, MA:\n\t\t\t\t\tCambridge Healthtech Institute;2021:\n\t\t\t\t\t16.","DOI":"10.5858\/arpa.2020-0716-SA"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/145\/7\/797\/2848215\/i1543-2165-145-7-797.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/145\/7\/797\/2848215\/i1543-2165-145-7-797.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:41:35Z","timestamp":1764790895000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/145\/7\/article-p797.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,8]]},"references-count":82,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,3,8]]},"published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2020-0716-sa","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,8]]}}}